{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:37:05Z","timestamp":1784000225316,"version":"3.55.0"},"reference-count":190,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2022ZDZX0023"],"award-info":[{"award-number":["2022ZDZX0023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00415-023-11572-x","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T11:03:58Z","timestamp":1674558238000},"page":"2483-2503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The updated development of blood-based biomarkers for Huntington\u2019s disease"],"prefix":"10.1007","volume":"270","author":[{"given":"Sirui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-1151","authenticated-orcid":false,"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"issue":"4","key":"11572_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204\u2013216. https:\/\/doi.org\/10.1038\/nrneurol.2014.24","journal-title":"Nat Rev Neurol"},{"key":"11572_CR2","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Primers 1:15005. https:\/\/doi.org\/10.1038\/nrdp.2015.5","journal-title":"Nat Rev Dis Primers"},{"key":"11572_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041561","author":"L Przybyl","year":"2021","unstructured":"Przybyl L, Wozna-Wysocka M, Kozlowska E, Fiszer A (2021) What, when and how to measure-peripheral biomarkers in therapy of Huntington\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22041561","journal-title":"Int J Mol Sci"},{"issue":"10","key":"11572_CR4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"SJ Evans","year":"2013","unstructured":"Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L (2013) Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 84(10):1156\u20131160. https:\/\/doi.org\/10.1136\/jnnp-2012-304636","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"11572_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord 29(1):105\u2013114. https:\/\/doi.org\/10.1002\/mds.25717","journal-title":"Mov Disord"},{"issue":"6","key":"11572_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-e","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72(6):971\u2013983. https:\/\/doi.org\/10.1016\/0092-8674(93)90585-e","journal-title":"Cell"},{"issue":"10","key":"11572_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 16(10):529\u2013546. https:\/\/doi.org\/10.1038\/s41582-020-0389-4","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"11572_CR8","first-page":"16","volume":"59","author":"DC Rubinsztein","year":"1996","unstructured":"Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats. Am J Hum Genet 59(1):16\u201322","journal-title":"Am J Hum Genet"},{"issue":"7","key":"11572_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/s1474-4422(22)00120-x","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Schobel S, Gantman EC et al (2022) A biological classification of Huntington\u2019s disease: the Integrated Staging System. Lancet Neurol 21(7):632\u2013644. https:\/\/doi.org\/10.1016\/s1474-4422(22)00120-x","journal-title":"Lancet Neurol"},{"issue":"4","key":"11572_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.neuron.2019.05.001","volume":"102","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR (2019) Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 102(4):899. https:\/\/doi.org\/10.1016\/j.neuron.2019.05.001","journal-title":"Neuron"},{"issue":"7","key":"11572_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/s1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC et al (2022) Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol 21(7):645\u2013658. https:\/\/doi.org\/10.1016\/s1474-4422(22)00121-1","journal-title":"Lancet Neurol"},{"issue":"3","key":"11572_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89\u201395. https:\/\/doi.org\/10.1067\/mcp.2001.113989","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"11572_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-020-00228-9","volume":"10","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Chen Y, Shang H (2021) Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Transl Neurodegener. 10(1):3. https:\/\/doi.org\/10.1186\/s40035-020-00228-9","journal-title":"Transl Neurodegener."},{"key":"11572_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mcn.2019.02.004","volume":"97","author":"P Zeun","year":"2019","unstructured":"Zeun P, Scahill RI, Tabrizi SJ, Wild EJ (2019) Fluid and imaging biomarkers for Huntington\u2019s disease. Mol Cell Neurosci 97:67\u201380. https:\/\/doi.org\/10.1016\/j.mcn.2019.02.004","journal-title":"Mol Cell Neurosci"},{"issue":"2","key":"11572_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord 11(2):136\u2013142. https:\/\/doi.org\/10.1002\/mds.870110204","journal-title":"Mov Disord"},{"issue":"6","key":"11572_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s1474-4422(11)70070-9","volume":"10","author":"DW Weir","year":"2011","unstructured":"Weir DW, Sturrock A, Leavitt BR (2011) Development of biomarkers for Huntington\u2019s disease. Lancet Neurol 10(6):573\u2013590. https:\/\/doi.org\/10.1016\/s1474-4422(11)70070-9","journal-title":"Lancet Neurol"},{"issue":"8","key":"11572_CR17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC et al (2008) Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79(8):874\u2013880. https:\/\/doi.org\/10.1136\/jnnp.2007.128728","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"11572_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.biopsych.2011.07.030","volume":"71","author":"EH Aylward","year":"2012","unstructured":"Aylward EH, Liu D, Nopoulos PC et al (2012) Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 71(9):822\u2013828. https:\/\/doi.org\/10.1016\/j.biopsych.2011.07.030","journal-title":"Biol Psychiatry"},{"issue":"11","key":"11572_CR19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s00415-008-0050-4","volume":"255","author":"CK Jurgens","year":"2008","unstructured":"Jurgens CK, van de Wiel L, van Es AC et al (2008) Basal ganglia volume and clinical correlates in \u201cpreclinical\u201d Huntington\u2019s disease. J Neurol 255(11):1785\u20131791. https:\/\/doi.org\/10.1007\/s00415-008-0050-4","journal-title":"J Neurol"},{"issue":"12","key":"11572_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11910-018-0890-y","volume":"18","author":"P Fazio","year":"2018","unstructured":"Fazio P, Paucar M, Svenningsson P, Varrone A (2018) Novel imaging biomarkers for Huntington\u2019s disease and other hereditary choreas. Curr Neurol Neurosci Rep 18(12):85. https:\/\/doi.org\/10.1007\/s11910-018-0890-y","journal-title":"Curr Neurol Neurosci Rep"},{"key":"11572_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","volume":"6","author":"JS Paulsen","year":"2014","unstructured":"Paulsen JS, Long JD, Johnson HJ et al (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78. https:\/\/doi.org\/10.3389\/fnagi.2014.00078","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"11572_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12(7):637\u2013649. https:\/\/doi.org\/10.1016\/s1474-4422(13)70088-7","journal-title":"Lancet Neurol"},{"issue":"9","key":"11572_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/s1474-4422(17)30161-8","volume":"16","author":"DJH Moss","year":"2017","unstructured":"Moss DJH, Pardi\u00f1as AF, Langbehn D et al (2017) Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study. Lancet Neurol 16(9):701\u2013711. https:\/\/doi.org\/10.1016\/s1474-4422(17)30161-8","journal-title":"Lancet Neurol"},{"issue":"24","key":"11572_CR24","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al (2019) Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 380(24):2307\u20132316. https:\/\/doi.org\/10.1056\/NEJMoa1900907","journal-title":"N Engl J Med"},{"key":"11572_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","volume":"6","author":"S Aguiar","year":"2017","unstructured":"Aguiar S, van der Gaag B, Cortese FAB (2017) RNAi mechanisms in Huntington\u2019s disease therapy: siRNA versus shRNA. Transl Neurodegener 6:30. https:\/\/doi.org\/10.1186\/s40035-017-0101-9","journal-title":"Transl Neurodegener"},{"issue":"4","key":"11572_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/jhd-229006","volume":"11","author":"C Estevez-Fraga","year":"2022","unstructured":"Estevez-Fraga C, Tabrizi SJ, Wild EJ (2022) Huntington\u2019s disease clinical trials corner: November 2022. J Huntingtons Dis 11(4):351\u2013367. https:\/\/doi.org\/10.3233\/jhd-229006","journal-title":"J Huntingtons Dis"},{"issue":"9","key":"11572_CR27","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"MM Evers","year":"2018","unstructured":"Evers MM, Miniarikova J, Juhas S et al (2018) AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model. Mol Ther 26(9):2163\u20132177. https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.021","journal-title":"Mol Ther"},{"issue":"7","key":"11572_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","volume":"25","author":"B Zeitler","year":"2019","unstructured":"Zeitler B, Froelich S, Marlen K et al (2019) Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease. Nat Med 25(7):1131\u20131142. https:\/\/doi.org\/10.1038\/s41591-019-0478-3","journal-title":"Nat Med"},{"key":"11572_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"FK Ekman","year":"2019","unstructured":"Ekman FK, Ojala DS, Adil MM, Lopez PA, Schaffer DV, Gaj T (2019) CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol Ther Nucleic Acids 17:829\u2013839. https:\/\/doi.org\/10.1016\/j.omtn.2019.07.009","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"11572_CR30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3727\/096368916x690863","volume":"25","author":"KD Fink","year":"2016","unstructured":"Fink KD, Deng P, Gutierrez J et al (2016) Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human Huntington\u2019s disease fibroblasts. Cell Transplant 25(4):677\u2013686. https:\/\/doi.org\/10.3727\/096368916x690863","journal-title":"Cell Transplant"},{"issue":"5","key":"11572_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1073858410390378","volume":"17","author":"DE Ehrnhoefer","year":"2011","unstructured":"Ehrnhoefer DE, Sutton L, Hayden MR (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17(5):475\u2013492. https:\/\/doi.org\/10.1177\/1073858410390378","journal-title":"Neuroscientist"},{"issue":"5","key":"11572_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.molcel.2018.07.032","volume":"71","author":"A Ast","year":"2018","unstructured":"Ast A, Buntru A, Schindler F et al (2018) mHTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington\u2019s disease. Mol Cell 71(5):675-688.e6. https:\/\/doi.org\/10.1016\/j.molcel.2018.07.032","journal-title":"Mol Cell"},{"issue":"1","key":"11572_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1471-4159.2005.03348.x","volume":"95","author":"G Hoffner","year":"2005","unstructured":"Hoffner G, Island ML, Djian P (2005) Purification of neuronal inclusions of patients with Huntington\u2019s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J Neurochem 95(1):125\u2013136. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03348.x","journal-title":"J Neurochem"},{"key":"11572_CR34","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024240","author":"M Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC (2017) Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a024240","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Pt 4","key":"11572_CR35","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY et al (2008) Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 131(Pt 4):1057\u20131068. https:\/\/doi.org\/10.1093\/brain\/awn025","journal-title":"Brain"},{"issue":"4","key":"11572_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2217\/nmt-2019-0033","volume":"10","author":"A Neueder","year":"2020","unstructured":"Neueder A, Orth M (2020) Mitochondrial biology and the identification of biomarkers of Huntington\u2019s disease. Neurodegener Dis Manag 10(4):243\u2013255. https:\/\/doi.org\/10.2217\/nmt-2019-0033","journal-title":"Neurodegener Dis Manag"},{"issue":"8","key":"11572_CR37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov AV, Gutekunst CA, Leavitt BR et al (2002) Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat Neurosci 5(8):731\u2013736. https:\/\/doi.org\/10.1038\/nn884","journal-title":"Nat Neurosci"},{"key":"11572_CR38","doi-asserted-by":"publisher","first-page":"577380","DOI":"10.1016\/j.jneuroim.2020.577380","volume":"348","author":"PAC Valad\u00e3o","year":"2020","unstructured":"Valad\u00e3o PAC, Santos KBS, Ferreira EVTH et al (2020) Inflammation in Huntington\u2019s disease: a few new twists on an old tale. J Neuroimmunol 348:577380. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577380","journal-title":"J Neuroimmunol"},{"issue":"3","key":"11572_CR39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41380-018-0021-9","volume":"24","author":"HL Denis","year":"2019","unstructured":"Denis HL, Lauruol F, Cicchetti F (2019) Are immunotherapies for Huntington\u2019s disease a realistic option? Mol Psychiatry 24(3):364\u2013377. https:\/\/doi.org\/10.1038\/s41380-018-0021-9","journal-title":"Mol Psychiatry"},{"issue":"4","key":"11572_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nn.3668","volume":"17","author":"A Crotti","year":"2014","unstructured":"Crotti A, Benner C, Kerman BE et al (2014) Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci 17(4):513\u2013521. https:\/\/doi.org\/10.1038\/nn.3668","journal-title":"Nat Neurosci"},{"key":"11572_CR41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64674","author":"R Kacher","year":"2021","unstructured":"Kacher R, Lejeune FX, No\u00ebl S et al (2021) Propensity for somatic expansion increases over the course of life in Huntington disease. Elife. https:\/\/doi.org\/10.7554\/eLife.64674","journal-title":"Elife"},{"issue":"24","key":"11572_CR42","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","volume":"12","author":"L Kennedy","year":"2003","unstructured":"Kennedy L, Evans E, Chen CM et al (2003) Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 12(24):3359\u20133367. https:\/\/doi.org\/10.1093\/hmg\/ddg352","journal-title":"Hum Mol Genet"},{"issue":"16","key":"11572_CR43","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","volume":"18","author":"M Swami","year":"2009","unstructured":"Swami M, Hendricks AE, Gillis T et al (2009) Somatic expansion of the Huntington\u2019s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet 18(16):3039\u20133047. https:\/\/doi.org\/10.1093\/hmg\/ddp242","journal-title":"Hum Mol Genet"},{"issue":"1","key":"11572_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3233\/jhd-200429","volume":"10","author":"DG Monckton","year":"2021","unstructured":"Monckton DG (2021) The contribution of somatic expansion of the CAG repeat to symptomatic development in Huntington\u2019s disease: a historical perspective. J Huntingtons Dis 10(1):7\u201333. https:\/\/doi.org\/10.3233\/jhd-200429","journal-title":"J Huntingtons Dis"},{"issue":"15","key":"11572_CR45","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1093\/hmg\/ddaa139","volume":"29","author":"R Mouro Pinto","year":"2020","unstructured":"Mouro Pinto R, Arning L, Giordano JV et al (2020) Patterns of CAG repeat instability in the central nervous system and periphery in Huntington\u2019s disease and in spinocerebellar ataxia type 1. Hum Mol Genet 29(15):2551\u20132567. https:\/\/doi.org\/10.1093\/hmg\/ddaa139","journal-title":"Hum Mol Genet"},{"issue":"10","key":"11572_CR46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/hmg\/ddm054","volume":"16","author":"PF Shelbourne","year":"2007","unstructured":"Shelbourne PF, Keller-McGandy C, Bi WL et al (2007) Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet 16(10):1133\u20131142. https:\/\/doi.org\/10.1093\/hmg\/ddm054","journal-title":"Hum Mol Genet"},{"issue":"17","key":"11572_CR47","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/hmg\/9.17.2539","volume":"9","author":"L Kennedy","year":"2000","unstructured":"Kennedy L, Shelbourne PF (2000) Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington\u2019s disease? Hum Mol Genet 9(17):2539\u20132544. https:\/\/doi.org\/10.1093\/hmg\/9.17.2539","journal-title":"Hum Mol Genet"},{"issue":"11","key":"11572_CR48","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1371\/journal.pcbi.0030235","volume":"3","author":"S Kaplan","year":"2007","unstructured":"Kaplan S, Itzkovitz S, Shapiro E (2007) A universal mechanism ties genotype to phenotype in trinucleotide diseases. PLoS Comput Biol 3(11):e235. https:\/\/doi.org\/10.1371\/journal.pcbi.0030235","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"11572_CR49","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium","year":"2019","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium (2019) CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. Cell 178(4):887\u2013900.e14. https:\/\/doi.org\/10.1016\/j.cell.2019.06.036","journal-title":"Cell"},{"key":"11572_CR50","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ebiom.2019.09.020","volume":"48","author":"M Ciosi","year":"2019","unstructured":"Ciosi M, Maxwell A, Cumming SA et al (2019) A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine 48:568\u2013580. https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.020","journal-title":"EBioMedicine"},{"key":"11572_CR51","doi-asserted-by":"publisher","first-page":"101358","DOI":"10.1016\/j.arr.2021.101358","volume":"69","author":"CL Chuang","year":"2021","unstructured":"Chuang CL, Demontis F (2021) Systemic manifestation and contribution of peripheral tissues to Huntington\u2019s disease pathogenesis. Ageing Res Rev 69:101358. https:\/\/doi.org\/10.1016\/j.arr.2021.101358","journal-title":"Ageing Res Rev"},{"issue":"2","key":"11572_CR52","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","volume":"219","author":"J Sassone","year":"2009","unstructured":"Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A (2009) Huntington\u2019s disease: the current state of research with peripheral tissues. Exp Neurol 219(2):385\u2013397. https:\/\/doi.org\/10.1016\/j.expneurol.2009.05.012","journal-title":"Exp Neurol"},{"key":"11572_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116089","author":"L G\u00f3mez-Jaramillo","year":"2022","unstructured":"G\u00f3mez-Jaramillo L, Cano-Cano F, Gonz\u00e1lez-Montelongo MDC, Campos-Caro A, Aguilar-Diosdado M, Arroba AI (2022) A new perspective on Huntington\u2019s disease: how a neurological disorder influences the peripheral tissues. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23116089","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11572_CR54","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41467-022-28653-6","volume":"13","author":"CG Keller","year":"2022","unstructured":"Keller CG, Shin Y, Monteys AM et al (2022) An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat Commun 13(1):1150. https:\/\/doi.org\/10.1038\/s41467-022-28653-6","journal-title":"Nat Commun"},{"issue":"1","key":"11572_CR55","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41467-021-21637-y","volume":"12","author":"M Eshraghi","year":"2021","unstructured":"Eshraghi M, Karunadharma PP, Blin J et al (2021) Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington disease. Nat Commun 12(1):1461. https:\/\/doi.org\/10.1038\/s41467-021-21637-y","journal-title":"Nat Commun"},{"issue":"1","key":"11572_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ab.2009.08.001","volume":"395","author":"A Weiss","year":"2009","unstructured":"Weiss A, Abramowski D, Bibel M et al (2009) Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington\u2019s disease. Anal Biochem 395(1):8\u201315. https:\/\/doi.org\/10.1016\/j.ab.2009.08.001","journal-title":"Anal Biochem"},{"key":"11572_CR57","doi-asserted-by":"publisher","first-page":"Rrn1205","DOI":"10.1371\/currents.RRN1205","volume":"2","author":"M Moscovitch-Lopatin","year":"2010","unstructured":"Moscovitch-Lopatin M, Weiss A, Rosas HD et al (2010) Optimization of an HTRF assay for the detection of soluble mutant huntingtin in human buffy coats: a potential biomarker in blood for Huntington disease. PLoS Curr. 2:Rrn1205. https:\/\/doi.org\/10.1371\/currents.RRN1205","journal-title":"PLoS Curr."},{"issue":"13","key":"11572_CR58","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1212\/WNL.0b013e3182a55ede","volume":"81","author":"M Moscovitch-Lopatin","year":"2013","unstructured":"Moscovitch-Lopatin M, Goodman RE, Eberly S et al (2013) HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology 81(13):1134\u20131140. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a55ede","journal-title":"Neurology"},{"issue":"12","key":"11572_CR59","doi-asserted-by":"publisher","first-page":"e0189891","DOI":"10.1371\/journal.pone.0189891","volume":"12","author":"DJ Hensman Moss","year":"2017","unstructured":"Hensman Moss DJ, Robertson N, Farmer R et al (2017) Quantification of huntingtin protein species in Huntington\u2019s disease patient leukocytes using optimised electrochemiluminescence immunoassays. PLoS ONE 12(12):e0189891. https:\/\/doi.org\/10.1371\/journal.pone.0189891","journal-title":"PLoS ONE"},{"issue":"10","key":"11572_CR60","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1172\/jci64565","volume":"122","author":"A Weiss","year":"2012","unstructured":"Weiss A, Tr\u00e4ger U, Wild EJ et al (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression. J Clin Invest 122(10):3731\u20133736. https:\/\/doi.org\/10.1172\/jci64565","journal-title":"J Clin Invest"},{"key":"11572_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc2888","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues FB, Byrne LM, Tortelli R et al (2020) Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abc2888","journal-title":"Sci Transl Med."},{"key":"11572_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7108","author":"LM Byrne","year":"2018","unstructured":"Byrne LM, Rodrigues FB, Johnson EB et al (2018) Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aat7108","journal-title":"Sci Transl Med."},{"issue":"5","key":"11572_CR63","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/jci80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest 125(5):1979\u20131986. https:\/\/doi.org\/10.1172\/jci80743","journal-title":"J Clin Invest"},{"issue":"1","key":"11572_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Keiser MS, Davidson BL (2017) CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther 25(1):12\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2016.11.010","journal-title":"Mol Ther"},{"issue":"1","key":"11572_CR65","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-016-0128-x","volume":"11","author":"C Agust\u00edn-Pav\u00f3n","year":"2016","unstructured":"Agust\u00edn-Pav\u00f3n C, Mielcarek M, Garriga-Canut M, Isalan M (2016) Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener 11(1):64. https:\/\/doi.org\/10.1186\/s13024-016-0128-x","journal-title":"Mol Neurodegener"},{"issue":"7781","key":"11572_CR66","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","volume":"575","author":"Z Li","year":"2019","unstructured":"Li Z, Wang C, Wang Z et al (2019) Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature 575(7781):203\u2013209. https:\/\/doi.org\/10.1038\/s41586-019-1722-1","journal-title":"Nature"},{"issue":"5","key":"11572_CR67","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/aps.2018.11","volume":"39","author":"RJ Harding","year":"2018","unstructured":"Harding RJ, Tong YF (2018) Proteostasis in Huntington\u2019s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol Sin 39(5):754\u2013769. https:\/\/doi.org\/10.1038\/aps.2018.11","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"11572_CR68","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"11572_CR69","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76(9):1035\u20131048. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1534","journal-title":"JAMA Neurol"},{"issue":"11","key":"11572_CR70","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1007\/s12035-020-02035-9","volume":"57","author":"G Palermo","year":"2020","unstructured":"Palermo G, Mazzucchi S, Della Vecchia A et al (2020) Different clinical contexts of use of blood neurofilament light chain protein in the spectrum of neurodegenerative diseases. Mol Neurobiol 57(11):4667\u20134691. https:\/\/doi.org\/10.1007\/s12035-020-02035-9","journal-title":"Mol Neurobiol"},{"key":"11572_CR71","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gissl\u00e9n","year":"2016","unstructured":"Gissl\u00e9n M, Price RW, Andreasson U et al (2016) Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3:135\u2013140. https:\/\/doi.org\/10.1016\/j.ebiom.2015.11.036","journal-title":"EBioMedicine"},{"issue":"10","key":"11572_CR72","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655\u20131661. https:\/\/doi.org\/10.1515\/cclm-2015-1195","journal-title":"Clin Chem Lab Med"},{"key":"11572_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105411","author":"S Mart\u00ed-Mart\u00ednez","year":"2022","unstructured":"Mart\u00ed-Mart\u00ednez S, Valor LM (2022) A glimpse of molecular biomarkers in Huntington\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23105411","journal-title":"Int J Mol Sci"},{"issue":"8","key":"11572_CR74","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/s1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol 16(8):601\u2013609. https:\/\/doi.org\/10.1016\/s1474-4422(17)30124-2","journal-title":"Lancet Neurol"},{"issue":"13","key":"11572_CR75","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/wnl.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IO, Dick KM et al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87(13):1329\u20131336. https:\/\/doi.org\/10.1212\/wnl.0000000000003154","journal-title":"Neurology"},{"issue":"10","key":"11572_CR76","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/wnl.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of Parkinsonian disorder. Neurology 88(10):930\u2013937. https:\/\/doi.org\/10.1212\/wnl.0000000000003680","journal-title":"Neurology"},{"issue":"8","key":"11572_CR77","doi-asserted-by":"publisher","first-page":"e717","DOI":"10.1212\/wnl.0000000000005005","volume":"90","author":"EB Johnson","year":"2018","unstructured":"Johnson EB, Byrne LM, Gregory S et al (2018) Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology 90(8):e717\u2013e723. https:\/\/doi.org\/10.1212\/wnl.0000000000005005","journal-title":"Neurology"},{"key":"11572_CR78","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.parkreldis.2021.04.017","volume":"87","author":"GM Parkin","year":"2021","unstructured":"Parkin GM, Corey-Bloom J, Snell C, Castleton J, Thomas EA (2021) Plasma neurofilament light in Huntington\u2019s disease: a marker for disease onset, but not symptom progression. Parkinsonism Relat Disord 87:32\u201338. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.04.017","journal-title":"Parkinsonism Relat Disord"},{"key":"11572_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2022.02.023","volume":"97","author":"GM Parkin","year":"2022","unstructured":"Parkin GM, Corey-Bloom J, Long JD, Snell C, Smith H, Thomas EA (2022) Associations between prognostic index scores and plasma neurofilament light in Huntington\u2019s disease. Parkinsonism Relat Disord 97:25\u201328. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.02.023","journal-title":"Parkinsonism Relat Disord"},{"key":"11572_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29027","author":"LM Byrne","year":"2022","unstructured":"Byrne LM, Schultz JL, Rodrigues FB et al (2022) Neurofilament light protein as a potential blood biomarker for Huntington\u2019s disease in children. Mov Disord. https:\/\/doi.org\/10.1002\/mds.29027","journal-title":"Mov Disord"},{"issue":"6","key":"11572_CR81","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/s1474-4422(20)30143-5","volume":"19","author":"RI Scahill","year":"2020","unstructured":"Scahill RI, Zeun P, Osborne-Crowley K et al (2020) Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol 19(6):502\u2013512. https:\/\/doi.org\/10.1016\/s1474-4422(20)30143-5","journal-title":"Lancet Neurol"},{"issue":"7113","key":"11572_CR82","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787\u2013795. https:\/\/doi.org\/10.1038\/nature05292","journal-title":"Nature"},{"key":"11572_CR83","doi-asserted-by":"publisher","first-page":"9187195","DOI":"10.1155\/2020\/9187195","volume":"2020","author":"Q Tang","year":"2020","unstructured":"Tang Q, Liu H, Shi XJ, Cheng Y (2020) Blood oxidative stress marker aberrations in patients with Huntington\u2019s disease: a meta-analysis study. Oxid Med Cell Longev 2020:9187195. https:\/\/doi.org\/10.1155\/2020\/9187195","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"11572_CR84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/jhd-170273","volume":"7","author":"E Silajd\u017ei\u0107","year":"2018","unstructured":"Silajd\u017ei\u0107 E, Bj\u00f6rkqvist M (2018) A critical evaluation of wet biomarkers for Huntington\u2019s disease: current status and ways forward. J Huntingtons Dis 7(2):109\u2013135. https:\/\/doi.org\/10.3233\/jhd-170273","journal-title":"J Huntingtons Dis"},{"issue":"6","key":"11572_CR85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2174\/1389450117666160401120514","volume":"18","author":"AN Carvalho","year":"2017","unstructured":"Carvalho AN, Firuzi O, Gama MJ, Horssen JV, Saso L (2017) Oxidative stress and antioxidants in neurological diseases: is there still hope? Curr Drug Targets 18(6):705\u2013718. https:\/\/doi.org\/10.2174\/1389450117666160401120514","journal-title":"Curr Drug Targets"},{"issue":"5","key":"11572_CR86","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1111\/bcp.14656","volume":"87","author":"MPJ van Diemen","year":"2021","unstructured":"van Diemen MPJ, Hart EP, Abbruscato A et al (2021) Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington\u2019s disease, a 2-part study. Br J Clin Pharmacol 87(5):2290\u20132302. https:\/\/doi.org\/10.1111\/bcp.14656","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"11572_CR87","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K et al (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG. Neurology 66(2):250\u2013252. https:\/\/doi.org\/10.1212\/01.wnl.0000194318.74946.b6","journal-title":"Neurology"},{"issue":"3","key":"11572_CR88","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nbd.2012.02.012","volume":"46","author":"JD Long","year":"2012","unstructured":"Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS (2012) 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 46(3):625\u2013634. https:\/\/doi.org\/10.1016\/j.nbd.2012.02.012","journal-title":"Neurobiol Dis"},{"issue":"6","key":"11572_CR89","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/1354750x.2014.935955","volume":"19","author":"I Ciancarelli","year":"2014","unstructured":"Ciancarelli I, De Amicis D, Di Massimo C et al (2014) Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington\u2019s patients. Biomarkers 19(6):452\u2013456. https:\/\/doi.org\/10.3109\/1354750x.2014.935955","journal-title":"Biomarkers"},{"issue":"15","key":"11572_CR90","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1021\/jm200605a","volume":"54","author":"I T\u00fanez","year":"2011","unstructured":"T\u00fanez I, S\u00e1nchez-L\u00f3pez F, Ag\u00fcera E, Fern\u00e1ndez-Bola\u00f1os R, S\u00e1nchez FM, Tasset-Cuevas I (2011) Important role of oxidative stress biomarkers in Huntington\u2019s disease. J Med Chem 54(15):5602\u20135606. https:\/\/doi.org\/10.1021\/jm200605a","journal-title":"J Med Chem"},{"issue":"2","key":"11572_CR91","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","volume":"359","author":"CM Chen","year":"2007","unstructured":"Chen CM, Wu YR, Cheng ML et al (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington\u2019s disease patients. Biochem Biophys Res Commun 359(2):335\u2013340. https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.093","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"11572_CR92","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1212\/WNL.0b013e318293e1a1","volume":"80","author":"B Borowsky","year":"2013","unstructured":"Borowsky B, Warner J, Leavitt BR et al (2013) 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 80(21):1934\u20131941. https:\/\/doi.org\/10.1212\/WNL.0b013e318293e1a1","journal-title":"Neurology"},{"issue":"6","key":"11572_CR93","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2217\/bmm.12.84","volume":"6","author":"A Killoran","year":"2012","unstructured":"Killoran A, Biglan KM (2012) 8-OHdG: its (limited) potential as a biomarker for Huntington\u2019s disease. Biomark Med 6(6):777\u2013780. https:\/\/doi.org\/10.2217\/bmm.12.84","journal-title":"Biomark Med"},{"issue":"Pt B","key":"11572_CR94","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.expneurol.2017.06.017","volume":"298","author":"GF Crotty","year":"2017","unstructured":"Crotty GF, Ascherio A, Schwarzschild MA (2017) Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol 298(Pt B):210\u2013224. https:\/\/doi.org\/10.1016\/j.expneurol.2017.06.017","journal-title":"Exp Neurol"},{"issue":"3","key":"11572_CR95","doi-asserted-by":"publisher","first-page":"e0173731","DOI":"10.1371\/journal.pone.0173731","volume":"12","author":"M Wen","year":"2017","unstructured":"Wen M, Zhou B, Chen YH et al (2017) Serum uric acid levels in patients with Parkinson\u2019s disease: a meta-analysis. PLoS ONE 12(3):e0173731. https:\/\/doi.org\/10.1371\/journal.pone.0173731","journal-title":"PLoS ONE"},{"issue":"2","key":"11572_CR96","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.22907","volume":"25","author":"P Auinger","year":"2010","unstructured":"Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington\u2019s disease progression. Mov Disord 25(2):224\u2013228. https:\/\/doi.org\/10.1002\/mds.22907","journal-title":"Mov Disord"},{"key":"11572_CR97","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fnins.2020.00073","volume":"14","author":"J Corey-Bloom","year":"2020","unstructured":"Corey-Bloom J, Haque A, Aboufadel S et al (2020) Uric acid as a potential peripheral biomarker for disease features in Huntington\u2019s patients. Front Neurosci 14:73. https:\/\/doi.org\/10.3389\/fnins.2020.00073","journal-title":"Front Neurosci"},{"issue":"11","key":"11572_CR98","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","volume":"21","author":"S Campesan","year":"2011","unstructured":"Campesan S, Green EW, Breda C et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington\u2019s disease. Curr Biol 21(11):961\u2013966. https:\/\/doi.org\/10.1016\/j.cub.2011.04.028","journal-title":"Curr Biol"},{"issue":"8","key":"11572_CR99","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","volume":"279","author":"GJ Guillemin","year":"2012","unstructured":"Guillemin GJ (2012) Quinolinic acid, the inescapable neurotoxin. Febs J 279(8):1356\u20131365. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08485.x","journal-title":"Febs J"},{"key":"11572_CR100","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.semcdb.2015.03.002","volume":"40","author":"DC Maddison","year":"2015","unstructured":"Maddison DC, Giorgini F (2015) The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol 40:134\u2013141. https:\/\/doi.org\/10.1016\/j.semcdb.2015.03.002","journal-title":"Semin Cell Dev Biol"},{"key":"11572_CR101","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","volume":"1780","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Byrne LM, Wild EJ (2018) Biofluid biomarkers in Huntington\u2019s disease. Methods Mol Biol 1780:329\u2013396. https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_17","journal-title":"Methods Mol Biol"},{"issue":"3","key":"11572_CR102","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","volume":"93","author":"N Stoy","year":"2005","unstructured":"Stoy N, Mackay GM, Forrest CM et al (2005) Tryptophan metabolism and oxidative stress in patients with Huntington\u2019s disease. J Neurochem 93(3):611\u2013623. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03070.x","journal-title":"J Neurochem"},{"issue":"1","key":"11572_CR103","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","volume":"112","author":"CM Forrest","year":"2010","unstructured":"Forrest CM, Mackay GM, Stoy N et al (2010) Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington\u2019s disease. J Neurochem 112(1):112\u2013122. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06442.x","journal-title":"J Neurochem"},{"issue":"7","key":"11572_CR104","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/acn3.214","volume":"2","author":"HD Rosas","year":"2015","unstructured":"Rosas HD, Doros G, Bhasin S et al (2015) A systems-level \u201cmisunderstanding\u201d: the plasma metabolome in Huntington\u2019s disease. Ann Clin Transl Neurol 2(7):756\u2013768. https:\/\/doi.org\/10.1002\/acn3.214","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"11572_CR105","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-010-0742-6","volume":"120","author":"S Gabery","year":"2010","unstructured":"Gabery S, Murphy K, Schultz K et al (2010) Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol 120(6):777\u2013788. https:\/\/doi.org\/10.1007\/s00401-010-0742-6","journal-title":"Acta Neuropathol"},{"issue":"3","key":"11572_CR106","doi-asserted-by":"publisher","first-page":"e4962","DOI":"10.1371\/journal.pone.0004962","volume":"4","author":"N Saleh","year":"2009","unstructured":"Saleh N, Moutereau S, Durr A et al (2009) Neuroendocrine disturbances in Huntington\u2019s disease. PLoS ONE 4(3):e4962. https:\/\/doi.org\/10.1371\/journal.pone.0004962","journal-title":"PLoS ONE"},{"issue":"7","key":"11572_CR107","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1371\/journal.pone.0000647","volume":"2","author":"F Mochel","year":"2007","unstructured":"Mochel F, Charles P, Seguin F et al (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2(7):e647. https:\/\/doi.org\/10.1371\/journal.pone.0000647","journal-title":"PLoS ONE"},{"issue":"2","key":"11572_CR108","first-page":"199","volume":"28","author":"M Markianos","year":"2007","unstructured":"Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2007) Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington\u2019s disease. Neuro Endocrinol Lett 28(2):199\u2013203","journal-title":"Neuro Endocrinol Lett"},{"issue":"10","key":"11572_CR109","doi-asserted-by":"publisher","first-page":"e0138848","DOI":"10.1371\/journal.pone.0138848","volume":"10","author":"E Kalliolia","year":"2015","unstructured":"Kalliolia E, Silajd\u017ei\u0107 E, Nambron R et al (2015) A 24-hour study of the hypothalamo-pituitary axes in Huntington\u2019s disease. PLoS ONE 10(10):e0138848. https:\/\/doi.org\/10.1371\/journal.pone.0138848","journal-title":"PLoS ONE"},{"issue":"1","key":"11572_CR110","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/0022-510x(95)00114-h","volume":"132","author":"F Leblhuber","year":"1995","unstructured":"Leblhuber F, Peichl M, Neubauer C et al (1995) Serum dehydroepiandrosterone and cortisol measurements in Huntington\u2019s chorea. J Neurol Sci 132(1):76\u201379. https:\/\/doi.org\/10.1016\/0022-510x(95)00114-h","journal-title":"J Neurol Sci"},{"issue":"4","key":"11572_CR111","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1210\/jc.2008-2543","volume":"94","author":"NA Aziz","year":"2009","unstructured":"Aziz NA, Pijl H, Fr\u00f6lich M, van der Graaf AW, Roelfsema F, Roos RA (2009) Increased hypothalamic-pituitary-adrenal axis activity in Huntington\u2019s disease. J Clin Endocrinol Metab 94(4):1223\u20131228. https:\/\/doi.org\/10.1210\/jc.2008-2543","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"11572_CR112","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/jne.12255","volume":"27","author":"AA Hubers","year":"2015","unstructured":"Hubers AA, van der Mast RC, Pereira AM et al (2015) Hypothalamic-pituitary-adrenal axis functioning in Huntington\u2019s disease and its association with depressive symptoms and suicidality. J Neuroendocrinol 27(3):234\u2013244. https:\/\/doi.org\/10.1111\/jne.12255","journal-title":"J Neuroendocrinol"},{"issue":"11","key":"11572_CR113","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.psyneuen.2012.10.020","volume":"38","author":"CA Shirbin","year":"2013","unstructured":"Shirbin CA, Chua P, Churchyard A et al (2013) Cortisol and depression in pre-diagnosed and early stage Huntington\u2019s disease. Psychoneuroendocrinology 38(11):2439\u20132447. https:\/\/doi.org\/10.1016\/j.psyneuen.2012.10.020","journal-title":"Psychoneuroendocrinology"},{"key":"11572_CR114","doi-asserted-by":"publisher","first-page":"594945","DOI":"10.3389\/fnins.2020.594945","volume":"14","author":"NP Rocha","year":"2020","unstructured":"Rocha NP, Cleary C, Colpo GD, Furr Stimming E, Teixeira AL (2020) Peripheral levels of renin-angiotensin system components are associated with cognitive performance in Huntington\u2019s disease. Front Neurosci 14:594945. https:\/\/doi.org\/10.3389\/fnins.2020.594945","journal-title":"Front Neurosci"},{"key":"11572_CR115","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1326-9-49","volume":"9","author":"DH Lee","year":"2014","unstructured":"Lee DH, Heidecke H, Schr\u00f6der A et al (2014) Increase of angiotensin II type 1 receptor auto-antibodies in Huntington\u2019s disease. Mol Neurodegener 9:49. https:\/\/doi.org\/10.1186\/1750-1326-9-49","journal-title":"Mol Neurodegener"},{"key":"11572_CR116","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1192\/bjp.171.4.393c","volume":"171","author":"N Taylor","year":"1997","unstructured":"Taylor N, Bramble D (1997) Sleep disturbance and Huntingdon\u2019s disease. Br J Psychiatry 171:393. https:\/\/doi.org\/10.1192\/bjp.171.4.393c","journal-title":"Br J Psychiatry"},{"key":"11572_CR117","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fpsyt.2019.00221","volume":"10","author":"R Herzog-Krzywoszanska","year":"2019","unstructured":"Herzog-Krzywoszanska R, Krzywoszanski L (2019) Sleep disorders in Huntington\u2019s disease. Front Psychiatry 10:221. https:\/\/doi.org\/10.3389\/fpsyt.2019.00221","journal-title":"Front Psychiatry"},{"issue":"8","key":"11572_CR118","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1212\/01.wnl.0000324283.57261.37","volume":"71","author":"EE Benarroch","year":"2008","unstructured":"Benarroch EE (2008) Suprachiasmatic nucleus and melatonin: reciprocal interactions and clinical correlations. Neurology 71(8):594\u2013598. https:\/\/doi.org\/10.1212\/01.wnl.0000324283.57261.37","journal-title":"Neurology"},{"issue":"4","key":"11572_CR119","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/j.1471-4159.2006.03807.x","volume":"97","author":"J Christofides","year":"2006","unstructured":"Christofides J, Bridel M, Egerton M et al (2006) Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington\u2019s disease or chronic brain injury. J Neurochem 97(4):1078\u20131088. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.03807.x","journal-title":"J Neurochem"},{"issue":"12","key":"11572_CR120","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00415-009-5196-1","volume":"256","author":"NA Aziz","year":"2009","unstructured":"Aziz NA, Pijl H, Fr\u00f6lich M et al (2009) Delayed onset of the diurnal melatonin rise in patients with Huntington\u2019s disease. J Neurol 256(12):1961\u20131965. https:\/\/doi.org\/10.1007\/s00415-009-5196-1","journal-title":"J Neurol"},{"issue":"12","key":"11572_CR121","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/mds.26003","volume":"29","author":"E Kalliolia","year":"2014","unstructured":"Kalliolia E, Silajd\u017ei\u0107 E, Nambron R et al (2014) Plasma melatonin is reduced in Huntington\u2019s disease. Mov Disord 29(12):1511\u20131515. https:\/\/doi.org\/10.1002\/mds.26003","journal-title":"Mov Disord"},{"issue":"4","key":"11572_CR122","first-page":"539","volume":"68","author":"A Adamczak-Ratajczak","year":"2017","unstructured":"Adamczak-Ratajczak A, Kupsz J, Owecki M et al (2017) Circadian rhythms of melatonin and cortisol in manifest Huntington\u2019s disease and in acute cortical ischemic stroke. J Physiol Pharmacol 68(4):539\u2013546","journal-title":"J Physiol Pharmacol"},{"issue":"41","key":"11572_CR123","doi-asserted-by":"publisher","first-page":"14496","DOI":"10.1523\/jneurosci.3059-11.2011","volume":"31","author":"X Wang","year":"2011","unstructured":"Wang X, Sirianni A, Pei Z et al (2011) The melatonin MT1 receptor axis modulates mutant huntingtin-mediated toxicity. J Neurosci 31(41):14496\u201314507. https:\/\/doi.org\/10.1523\/jneurosci.3059-11.2011","journal-title":"J Neurosci"},{"key":"11572_CR124","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbr.2014.01.048","volume":"264","author":"J Chakraborty","year":"2014","unstructured":"Chakraborty J, Nthenge-Ngumbau DN, Rajamma U, Mohanakumar KP (2014) Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington\u2019s disease. Behav Brain Res 264:91\u2013104. https:\/\/doi.org\/10.1016\/j.bbr.2014.01.048","journal-title":"Behav Brain Res"},{"issue":"41","key":"11572_CR125","doi-asserted-by":"publisher","first-page":"12764","DOI":"10.1523\/jneurosci.3566-09.2009","volume":"29","author":"ME Greenberg","year":"2009","unstructured":"Greenberg ME, Xu B, Lu B, Hempstead BL (2009) New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 29(41):12764\u201312767. https:\/\/doi.org\/10.1523\/jneurosci.3566-09.2009","journal-title":"J Neurosci"},{"key":"11572_CR126","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fnmol.2019.00335","volume":"12","author":"A Gutierrez","year":"2019","unstructured":"Gutierrez A, Corey-Bloom J, Thomas EA, Desplats P (2019) Evaluation of biochemical and epigenetic measures of peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in Huntington\u2019s disease patients. Front Mol Neurosci 12:335. https:\/\/doi.org\/10.3389\/fnmol.2019.00335","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"11572_CR127","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato C, Tartari M, Crotti A et al (2003) Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35(1):76\u201383. https:\/\/doi.org\/10.1038\/ng1219","journal-title":"Nat Genet"},{"issue":"5529","key":"11572_CR128","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293(5529):493\u2013498. https:\/\/doi.org\/10.1126\/science.1059581","journal-title":"Science"},{"issue":"4","key":"11572_CR129","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ajmg.b.30501","volume":"144b","author":"A Ciammola","year":"2007","unstructured":"Ciammola A, Sassone J, Cannella M et al (2007) Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients. Am J Med Genet B Neuropsychiatr Genet 144b(4):574\u2013577. https:\/\/doi.org\/10.1002\/ajmg.b.30501","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"1","key":"11572_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1755-5949.2008.00068.x","volume":"15","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Cannella M, Simonelli M et al (2009) Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington\u2019s disease. CNS Neurosci Ther Winter 15(1):1\u201311. https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00068.x","journal-title":"CNS Neurosci Ther Winter"},{"issue":"1\u20132","key":"11572_CR131","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jns.2011.12.014","volume":"315","author":"I Tasset","year":"2012","unstructured":"Tasset I, S\u00e1nchez-L\u00f3pez F, Ag\u00fcera E et al (2012) NGF and nitrosative stress in patients with Huntington\u2019s disease. J Neurol Sci 315(1\u20132):133\u2013136. https:\/\/doi.org\/10.1016\/j.jns.2011.12.014","journal-title":"J Neurol Sci"},{"issue":"8","key":"11572_CR132","doi-asserted-by":"publisher","first-page":"e22966","DOI":"10.1371\/journal.pone.0022966","volume":"6","author":"C Zuccato","year":"2011","unstructured":"Zuccato C, Marullo M, Vitali B et al (2011) Brain-derived neurotrophic factor in patients with Huntington\u2019s disease. PLoS ONE 6(8):e22966. https:\/\/doi.org\/10.1371\/journal.pone.0022966","journal-title":"PLoS ONE"},{"key":"11572_CR133","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fphys.2014.00231","volume":"5","author":"R Wang","year":"2014","unstructured":"Wang R, Ross CA, Cai H et al (2014) Metabolic and hormonal signatures in pre-manifest and manifest Huntington\u2019s disease patients. Front Physiol 5:231. https:\/\/doi.org\/10.3389\/fphys.2014.00231","journal-title":"Front Physiol"},{"issue":"1","key":"11572_CR134","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1038\/s41598-021-83000-x","volume":"11","author":"ZA Ou","year":"2021","unstructured":"Ou ZA, Byrne LM, Rodrigues FB et al (2021) Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington\u2019s disease. Sci Rep 11(1):3481. https:\/\/doi.org\/10.1038\/s41598-021-83000-x","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"11572_CR135","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s0006-8993(00)02237-x","volume":"866","author":"I Ferrer","year":"2000","unstructured":"Ferrer I, Goutan E, Mar\u00edn C, Rey MJ, Ribalta T (2000) Brain-derived neurotrophic factor in Huntington disease. Brain Res 866(1\u20132):257\u2013261. https:\/\/doi.org\/10.1016\/s0006-8993(00)02237-x","journal-title":"Brain Res"},{"issue":"2","key":"11572_CR136","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","volume":"105","author":"K Gharami","year":"2008","unstructured":"Gharami K, Xie Y, An JJ, Tonegawa S, Xu B (2008) Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington\u2019s disease phenotypes in mice. J Neurochem 105(2):369\u2013379. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05137.x","journal-title":"J Neurochem"},{"issue":"1","key":"11572_CR137","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118(1):127\u2013138. https:\/\/doi.org\/10.1016\/j.cell.2004.06.018","journal-title":"Cell"},{"issue":"8","key":"11572_CR138","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/npp.2015.349","volume":"41","author":"KR Maynard","year":"2016","unstructured":"Maynard KR, Hill JL, Calcaterra NE et al (2016) Functional role of BDNF production from unique promoters in aggression and serotonin signaling. Neuropsychopharmacology 41(8):1943\u20131955. https:\/\/doi.org\/10.1038\/npp.2015.349","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"11572_CR139","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.immuni.2019.03.016","volume":"50","author":"TR Hammond","year":"2019","unstructured":"Hammond TR, Marsh SE, Stevens B (2019) Immune signaling in neurodegeneration. Immunity 50(4):955\u2013974. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.016","journal-title":"Immunity"},{"issue":"9","key":"11572_CR140","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/mp.2011.28","volume":"16","author":"D Soulet","year":"2011","unstructured":"Soulet D, Cicchetti F (2011) The role of immunity in Huntington\u2019s disease. Mol Psychiatry 16(9):889\u2013902. https:\/\/doi.org\/10.1038\/mp.2011.28","journal-title":"Mol Psychiatry"},{"key":"11572_CR141","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","volume":"83","author":"M Politis","year":"2015","unstructured":"Politis M, Lahiri N, Niccolini F et al (2015) Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers. Neurobiol Dis 83:115\u2013121. https:\/\/doi.org\/10.1016\/j.nbd.2015.08.011","journal-title":"Neurobiol Dis"},{"key":"11572_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176363","author":"J Corey-Bloom","year":"2020","unstructured":"Corey-Bloom J, Fischer RS, Kim A et al (2020) Levels of interleukin-6 in saliva, but not plasma, correlate with clinical metrics in Huntington\u2019s disease patients and healthy control subjects. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21176363","journal-title":"Int J Mol Sci"},{"issue":"7","key":"11572_CR143","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1021\/pr0700753","volume":"6","author":"A Dalrymple","year":"2007","unstructured":"Dalrymple A, Wild EJ, Joubert R et al (2007) Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6(7):2833\u20132840. https:\/\/doi.org\/10.1021\/pr0700753","journal-title":"J Proteome Res"},{"issue":"8","key":"11572_CR144","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J et al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med 205(8):1869\u20131877. https:\/\/doi.org\/10.1084\/jem.20080178","journal-title":"J Exp Med"},{"issue":"7","key":"11572_CR145","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1179\/1743132812y.0000000073","volume":"34","author":"F S\u00e1nchez-L\u00f3pez","year":"2012","unstructured":"S\u00e1nchez-L\u00f3pez F, Tasset I, Ag\u00fcera E et al (2012) Oxidative stress and inflammation biomarkers in the blood of patients with Huntington\u2019s disease. Neurol Res 34(7):721\u2013724. https:\/\/doi.org\/10.1179\/1743132812y.0000000073","journal-title":"Neurol Res"},{"issue":"4","key":"11572_CR146","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/jhd-160213","volume":"5","author":"JA Bouwens","year":"2016","unstructured":"Bouwens JA, van Duijn E, Cobbaert CM, Roos RA, van der Mast RC, Giltay EJ (2016) Plasma cytokine levels in relation to neuropsychiatric symptoms and cognitive dysfunction in Huntington\u2019s disease. J Huntingtons Dis 5(4):369\u2013377. https:\/\/doi.org\/10.3233\/jhd-160213","journal-title":"J Huntingtons Dis"},{"key":"11572_CR147","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","volume":"44","author":"KH Chang","year":"2015","unstructured":"Chang KH, Wu YR, Chen YC, Chen CM (2015) Plasma inflammatory biomarkers for Huntington\u2019s disease patients and mouse model. Brain Behav Immun 44:121\u2013127. https:\/\/doi.org\/10.1016\/j.bbi.2014.09.011","journal-title":"Brain Behav Immun"},{"issue":"1","key":"11572_CR148","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0301-0082(97)00066-x","volume":"54","author":"KC Flanders","year":"1998","unstructured":"Flanders KC, Ren RF, Lippa CF (1998) Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 54(1):71\u201385. https:\/\/doi.org\/10.1016\/s0301-0082(97)00066-x","journal-title":"Prog Neurobiol"},{"key":"11572_CR149","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fnagi.2017.00193","volume":"9","author":"HM Yang","year":"2017","unstructured":"Yang HM, Yang S, Huang SS, Tang BS, Guo JF (2017) Microglial activation in the pathogenesis of Huntington\u2019s disease. Front Aging Neurosci 9:193. https:\/\/doi.org\/10.3389\/fnagi.2017.00193","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"11572_CR150","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1582-4934.2010.01011.x","volume":"15","author":"G Battaglia","year":"2011","unstructured":"Battaglia G, Cannella M, Riozzi B et al (2011) Early defect of transforming growth factor \u03b21 formation in Huntington\u2019s disease. J Cell Mol Med 15(3):555\u2013571. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01011.x","journal-title":"J Cell Mol Med"},{"key":"11572_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10133001","author":"K Plinta","year":"2021","unstructured":"Plinta K, Plewka A, W\u00f3jcik-P\u0119dziwiatr M, Zmarz\u0142y N, Rudzi\u0144ski M, Rudzi\u0144ska-Bar M (2021) Is TGF-\u03b21 a biomarker of Huntington\u2019s disease progression? J Clin Med. https:\/\/doi.org\/10.3390\/jcm10133001","journal-title":"J Clin Med"},{"key":"11572_CR152","doi-asserted-by":"publisher","first-page":"Rrn1231","DOI":"10.1371\/currents.RRN1231","volume":"3","author":"E Wild","year":"2011","unstructured":"Wild E, Magnusson A, Lahiri N et al (2011) Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS Curr. 3:Rrn1231. https:\/\/doi.org\/10.1371\/currents.RRN1231","journal-title":"PLoS Curr."},{"issue":"1","key":"11572_CR153","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/jhd-130049","volume":"2","author":"E Silajd\u017ei\u0107","year":"2013","unstructured":"Silajd\u017ei\u0107 E, Rezeli M, V\u00e9gv\u00e1ri \u00c1 et al (2013) A critical evaluation of inflammatory markers in Huntington\u2019s disease plasma. J Huntingtons Dis 2(1):125\u2013134. https:\/\/doi.org\/10.3233\/jhd-130049","journal-title":"J Huntingtons Dis"},{"key":"11572_CR154","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4615-4709-9_19","volume":"467","author":"B Widner","year":"1999","unstructured":"Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D (1999) Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 467:133\u2013138. https:\/\/doi.org\/10.1007\/978-1-4615-4709-9_19","journal-title":"Adv Exp Med Biol"},{"key":"11572_CR155","doi-asserted-by":"publisher","first-page":"101439","DOI":"10.1016\/j.molmet.2022.101439","volume":"57","author":"E Dickson","year":"2022","unstructured":"Dickson E, Soylu-Kucharz R, Peters\u00e9n \u00c5, Bj\u00f6rkqvist M (2022) Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington\u2019s disease mice. Mol Metab. 57:101439. https:\/\/doi.org\/10.1016\/j.molmet.2022.101439","journal-title":"Mol Metab."},{"issue":"2","key":"11572_CR156","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.expneurol.2007.12.026","volume":"210","author":"AO Goodman","year":"2008","unstructured":"Goodman AO, Murgatroyd PR, Medina-Gomez G et al (2008) The metabolic profile of early Huntington\u2019s disease\u2014a combined human and transgenic mouse study. Exp Neurol 210(2):691\u2013698. https:\/\/doi.org\/10.1016\/j.expneurol.2007.12.026","journal-title":"Exp Neurol"},{"issue":"3","key":"11572_CR157","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.25007","volume":"82","author":"JMM van der Burg","year":"2017","unstructured":"van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA (2017) Body weight is a robust predictor of clinical progression in Huntington disease. Ann Neurol 82(3):479\u2013483. https:\/\/doi.org\/10.1002\/ana.25007","journal-title":"Ann Neurol"},{"issue":"3","key":"11572_CR158","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neulet.2011.03.025","volume":"494","author":"V Leoni","year":"2011","unstructured":"Leoni V, Mariotti C, Nanetti L et al (2011) Whole body cholesterol metabolism is impaired in Huntington\u2019s disease. Neurosci Lett 494(3):245\u2013249. https:\/\/doi.org\/10.1016\/j.neulet.2011.03.025","journal-title":"Neurosci Lett"},{"issue":"6","key":"11572_CR159","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01725.x","volume":"260","author":"I Bj\u00f6rkhem","year":"2006","unstructured":"Bj\u00f6rkhem I (2006) Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 260(6):493\u2013508. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01725.x","journal-title":"J Intern Med"},{"key":"11572_CR160","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nbd.2013.03.013","volume":"55","author":"V Leoni","year":"2013","unstructured":"Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS (2013) Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis 55:37\u201343. https:\/\/doi.org\/10.1016\/j.nbd.2013.03.013","journal-title":"Neurobiol Dis"},{"issue":"Pt 11","key":"11572_CR161","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/brain\/awn212","volume":"131","author":"V Leoni","year":"2008","unstructured":"Leoni V, Mariotti C, Tabrizi SJ et al (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington\u2019s disease. Brain 131(Pt 11):2851\u20132859. https:\/\/doi.org\/10.1093\/brain\/awn212","journal-title":"Brain"},{"issue":"1","key":"11572_CR162","doi-asserted-by":"publisher","first-page":"20490","DOI":"10.1038\/s41598-020-77526-9","volume":"10","author":"A McGarry","year":"2020","unstructured":"McGarry A, Gaughan J, Hackmyer C et al (2020) Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington\u2019s disease for participants of varying functional disability: a pilot study. Sci Rep 10(1):20490. https:\/\/doi.org\/10.1038\/s41598-020-77526-9","journal-title":"Sci Rep"},{"key":"11572_CR163","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jnutbio.2015.12.001","volume":"31","author":"ML Cheng","year":"2016","unstructured":"Cheng ML, Chang KH, Wu YR, Chen CM (2016) Metabolic disturbances in plasma as biomarkers for Huntington\u2019s disease. J Nutr Biochem 31:38\u201344. https:\/\/doi.org\/10.1016\/j.jnutbio.2015.12.001","journal-title":"J Nutr Biochem"},{"issue":"2","key":"11572_CR164","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archneurol.2010.358","volume":"68","author":"F Mochel","year":"2011","unstructured":"Mochel F, Benaich S, Rabier D, Durr A (2011) Validation of plasma branched chain amino acids as biomarkers in Huntington disease. Arch Neurol 68(2):265\u2013267. https:\/\/doi.org\/10.1001\/archneurol.2010.358","journal-title":"Arch Neurol"},{"issue":"3","key":"11572_CR165","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ncb0309-228","volume":"11","author":"J Winter","year":"2009","unstructured":"Winter J, Jung S, Keller S, Gregory RI, Diederichs S (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11(3):228\u2013234. https:\/\/doi.org\/10.1038\/ncb0309-228","journal-title":"Nat Cell Biol"},{"issue":"1","key":"11572_CR166","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12929-021-00755-1","volume":"28","author":"CW Tung","year":"2021","unstructured":"Tung CW, Huang PY, Chan SC, Cheng PH, Yang SH (2021) The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington\u2019s disease. J Biomed Sci 28(1):59. https:\/\/doi.org\/10.1186\/s12929-021-00755-1","journal-title":"J Biomed Sci"},{"key":"11572_CR167","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-6606-7-46","volume":"7","author":"J Kocerha","year":"2014","unstructured":"Kocerha J, Xu Y, Prucha MS, Zhao D, Chan AW (2014) microRNA-128a dysregulation in transgenic Huntington\u2019s disease monkeys. Mol Brain 7:46. https:\/\/doi.org\/10.1186\/1756-6606-7-46","journal-title":"Mol Brain"},{"issue":"2","key":"11572_CR168","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/2211536604666150713105606","volume":"4","author":"E Das","year":"2015","unstructured":"Das E, Jana NR, Bhattacharyya NP (2015) Delayed cell cycle progression in STHdh(Q111)\/Hdh(Q111) cells, a cell model for Huntington\u2019s disease mediated by microRNA-19a, microRNA-146a and microRNA-432. Microrna 4(2):86\u2013100. https:\/\/doi.org\/10.2174\/2211536604666150713105606","journal-title":"Microrna"},{"issue":"9","key":"11572_CR169","doi-asserted-by":"publisher","first-page":"e0162788","DOI":"10.1371\/journal.pone.0162788","volume":"11","author":"T Kunkanjanawan","year":"2016","unstructured":"Kunkanjanawan T, Carter RL, Prucha MS, Yang J, Parnpai R, Chan AW (2016) miR-196a ameliorates cytotoxicity and cellular phenotype in transgenic Huntington\u2019s disease monkey neural cells. PLoS ONE 11(9):e0162788. https:\/\/doi.org\/10.1371\/journal.pone.0162788","journal-title":"PLoS ONE"},{"issue":"1","key":"11572_CR170","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12929-020-00636-z","volume":"27","author":"YY Wu","year":"2020","unstructured":"Wu YY, Kuo HC (2020) Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases. J Biomed Sci 27(1):49. https:\/\/doi.org\/10.1186\/s12929-020-00636-z","journal-title":"J Biomed Sci"},{"issue":"4","key":"11572_CR171","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","volume":"30","author":"MA Mori","year":"2019","unstructured":"Mori MA, Ludwig RG, Garcia-Martin R, Brand\u00e3o BB, Kahn CR (2019) Extracellular miRNAs: from biomarkers to mediators of physiology and disease. Cell Metab 30(4):656\u2013673. https:\/\/doi.org\/10.1016\/j.cmet.2019.07.011","journal-title":"Cell Metab"},{"issue":"10","key":"11572_CR172","doi-asserted-by":"publisher","first-page":"725","DOI":"10.18632\/aging.100603","volume":"5","author":"N Noren Hooten","year":"2013","unstructured":"Noren Hooten N, Fitzpatrick M, Wood WH 3rd et al (2013) Age-related changes in microRNA levels in serum. Aging (Albany NY) 5(10):725\u2013740. https:\/\/doi.org\/10.18632\/aging.100603","journal-title":"Aging (Albany NY)"},{"issue":"11","key":"11572_CR173","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1093\/hmg\/ddr111","volume":"20","author":"PM Gaughwin","year":"2011","unstructured":"Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bj\u00f6rkqvist M (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington\u2019s disease. Hum Mol Genet 20(11):2225\u20132237. https:\/\/doi.org\/10.1093\/hmg\/ddr111","journal-title":"Hum Mol Genet"},{"key":"11572_CR174","doi-asserted-by":"publisher","first-page":"657973","DOI":"10.3389\/fneur.2021.657973","volume":"12","author":"M Ferraldeschi","year":"2021","unstructured":"Ferraldeschi M, Romano S, Giglio S et al (2021) Circulating hsa-miR-323b-3p in Huntington\u2019s disease: a pilot study. Front Neurol 12:657973. https:\/\/doi.org\/10.3389\/fneur.2021.657973","journal-title":"Front Neurol"},{"issue":"1","key":"11572_CR175","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13023-017-0742-x","volume":"12","author":"KH Chang","year":"2017","unstructured":"Chang KH, Wu YR, Chen CM (2017) Down-regulation of miR-9* in the peripheral leukocytes of Huntington\u2019s disease patients. Orphanet J Rare Dis 12(1):185. https:\/\/doi.org\/10.1186\/s13023-017-0742-x","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"11572_CR176","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/mds.26457","volume":"30","author":"AG Hoss","year":"2015","unstructured":"Hoss AG, Lagomarsino VN, Frank S, Hadzi TC, Myers RH, Latourelle JC (2015) Study of plasma-derived miRNAs mimic differences in Huntington\u2019s disease brain. Mov Disord 30(14):1961\u20131964. https:\/\/doi.org\/10.1002\/mds.26457","journal-title":"Mov Disord"},{"key":"11572_CR177","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2016.05.005","volume":"108","author":"C D\u00edez-Planelles","year":"2016","unstructured":"D\u00edez-Planelles C, S\u00e1nchez-Lozano P, Crespo MC et al (2016) Circulating microRNAs in Huntington\u2019s disease: emerging mediators in metabolic impairment. Pharmacol Res 108:102\u2013110. https:\/\/doi.org\/10.1016\/j.phrs.2016.05.005","journal-title":"Pharmacol Res"},{"issue":"7","key":"11572_CR178","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/s1474-4422(22)00189-2","volume":"21","author":"C Saft","year":"2022","unstructured":"Saft C (2022) Huntington\u2019s disease: disappointments and new beginnings. Lancet Neurol 21(7):582\u2013584. https:\/\/doi.org\/10.1016\/s1474-4422(22)00189-2","journal-title":"Lancet Neurol"},{"issue":"2","key":"11572_CR179","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/jnc.15360","volume":"158","author":"FB Rodrigues","year":"2021","unstructured":"Rodrigues FB, Byrne LM, Lowe AJ et al (2021) Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington\u2019s disease. J Neurochem 158(2):539\u2013553. https:\/\/doi.org\/10.1111\/jnc.15360","journal-title":"J Neurochem"},{"issue":"Pt 3","key":"11572_CR180","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Tr\u00e4ger","year":"2014","unstructured":"Tr\u00e4ger U, Andre R, Lahiri N et al (2014) HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NF\u03baB pathway dysregulation. Brain 137(Pt 3):819\u2013833. https:\/\/doi.org\/10.1093\/brain\/awt355","journal-title":"Brain"},{"issue":"8","key":"11572_CR181","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.euroneuro.2014.05.004","volume":"24","author":"JA Bouwens","year":"2014","unstructured":"Bouwens JA, Hubers AA, van Duijn E et al (2014) Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington\u2019s disease. Eur Neuropsychopharmacol 24(8):1248\u20131256. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.05.004","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"11572_CR182","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1515\/cclm.1998.132","volume":"36","author":"F Leblhuber","year":"1998","unstructured":"Leblhuber F, Walli J, Jellinger K et al (1998) Activated immune system in patients with Huntington\u2019s disease. Clin Chem Lab Med 36(10):747\u2013750. https:\/\/doi.org\/10.1515\/cclm.1998.132","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"11572_CR183","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ymgme.2007.10.002","volume":"93","author":"M Markianos","year":"2008","unstructured":"Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2008) Low plasma total cholesterol in patients with Huntington\u2019s disease and first-degree relatives. Mol Genet Metab 93(3):341\u2013346. https:\/\/doi.org\/10.1016\/j.ymgme.2007.10.002","journal-title":"Mol Genet Metab"},{"issue":"5","key":"11572_CR184","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/jnnp.2010.208553","volume":"82","author":"E Salvatore","year":"2011","unstructured":"Salvatore E, Rinaldi C, Tucci T et al (2011) Growth hormone response to arginine test differentiates between two subgroups of Huntington\u2019s disease patients. J Neurol Neurosurg Psychiatry 82(5):543\u2013547. https:\/\/doi.org\/10.1136\/jnnp.2010.208553","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11572_CR185","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jns.2016.02.018","volume":"362","author":"SM Nielsen","year":"2016","unstructured":"Nielsen SM, Vinther-Jensen T, Nielsen JE et al (2016) Liver function in Huntington\u2019s disease assessed by blood biochemical analyses in a clinical setting. J Neurol Sci 362:326\u2013332. https:\/\/doi.org\/10.1016\/j.jns.2016.02.018","journal-title":"J Neurol Sci"},{"issue":"3","key":"11572_CR186","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1600-0404.1995.tb00438.x","volume":"91","author":"R Reilmann","year":"1995","unstructured":"Reilmann R, Rolf LH, Lange HW (1995) Decreased plasma alanine and isoleucine in Huntington\u2019s disease. Acta Neurol Scand 91(3):222\u2013224. https:\/\/doi.org\/10.1111\/j.1600-0404.1995.tb00438.x","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"11572_CR187","first-page":"779","volume":"20","author":"B Gruber","year":"2013","unstructured":"Gruber B, K\u0142aczkow G, Jaworska M et al (2013) Huntington\u2019 disease\u2013imbalance of amino acid levels in plasma of patients and mutation carriers. Ann Agric Environ Med 20(4):779\u2013783","journal-title":"Ann Agric Environ Med"},{"key":"11572_CR188","doi-asserted-by":"publisher","DOI":"10.1371\/currents.hd.c63b441d04bb6738c0234f91c2b3e312","author":"NA Aziz","year":"2015","unstructured":"Aziz NA, Onkenhout W, Kerstens HJ, Roos RA (2015) Cystathionine levels in patients with Huntington disease. PLoS Curr. https:\/\/doi.org\/10.1371\/currents.hd.c63b441d04bb6738c0234f91c2b3e312","journal-title":"PLoS Curr."},{"issue":"1","key":"11572_CR189","doi-asserted-by":"publisher","first-page":"e0146480","DOI":"10.1371\/journal.pone.0146480","volume":"11","author":"R Nambron","year":"2016","unstructured":"Nambron R, Silajd\u017ei\u0107 E, Kalliolia E et al (2016) A metabolic study of Huntington\u2019s disease. PLoS ONE 11(1):e0146480. https:\/\/doi.org\/10.1371\/journal.pone.0146480","journal-title":"PLoS ONE"},{"key":"11572_CR190","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12920-015-0083-3","volume":"8","author":"AG Hoss","year":"2015","unstructured":"Hoss AG, Labadorf A, Latourelle JC et al (2015) miR-10b-5p expression in Huntington\u2019s disease brain relates to age of onset and the extent of striatal involvement. BMC Med Genomics 8:10. https:\/\/doi.org\/10.1186\/s12920-015-0083-3","journal-title":"BMC Med Genomics"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11572-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11572-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11572-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:09:05Z","timestamp":1744211345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11572-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":190,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["11572"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11572-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}